252 related articles for article (PubMed ID: 10189134)
1. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy.
Cheng L; Sebo TJ; Cheville JC; Pisansky TM; Slezak J; Bergstralh EJ; Pacelli A; Neumann RM; Zincke H; Bostwick DG
Cancer; 1999 Mar; 85(6):1293-9. PubMed ID: 10189134
[TBL] [Abstract][Full Text] [Related]
2. Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity.
Grossfeld GD; Olumi AF; Connolly JA; Chew K; Gibney J; Bhargava V; Waldman FM; Carroll PR
J Urol; 1998 May; 159(5):1437-43. PubMed ID: 9554329
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors in prostate cancer.
Stattin P
Scand J Urol Nephrol Suppl; 1997; 185():1-46. PubMed ID: 9249905
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic relevance of proliferation marker Ki-67 (MIB 1), PCNA and p53 in combined surgically and radiologically treated cancers of the oropharynx and mouth cavity].
Sittel C; Ruiz S; Kvasnicka HM; Volling P; Jungehülsing M; Eckel HE
Laryngorhinootologie; 2000 Feb; 79(2):86-92. PubMed ID: 10738715
[TBL] [Abstract][Full Text] [Related]
5. Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy.
Bauer JJ; Connelly RR; Sesterhenn IA; Bettencourt MC; McLeod DG; Srivastava S; Moul JW
Cancer; 1997 Mar; 79(5):952-62. PubMed ID: 9041158
[TBL] [Abstract][Full Text] [Related]
6. p53 alteration in regional lymph node metastases from prostate carcinoma: a marker for progression?
Cheng L; Leibovich BC; Bergstralh EJ; Scherer BG; Pacelli A; Ramnani DM; Zincke H; Bostwick DG
Cancer; 1999 Jun; 85(11):2455-9. PubMed ID: 10357418
[TBL] [Abstract][Full Text] [Related]
7. p53 expression, proliferation marker Ki-S5, DNA content and serum PSA: possible biopotential markers in human prostatic cancer.
Papadopoulos I; Rudolph P; Wirth B; Weichert-Jacobsen K
Urology; 1996 Aug; 48(2):261-8. PubMed ID: 8753738
[TBL] [Abstract][Full Text] [Related]
8. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.
Bettencourt MC; Bauer JJ; Sesterhenn IA; Mostofi FK; McLeod DG; Moul JW
J Urol; 1996 Sep; 156(3):1064-8. PubMed ID: 8709308
[TBL] [Abstract][Full Text] [Related]
9. Nuclear DNA content, an adjunct to p53 and Ki-67 as a marker of resistance to radiation therapy in oral cavity and pharyngeal squamous cell carcinoma.
Raybaud H; Fortin A; Bairati I; Morency R; Monteil RA; Têtu B
Int J Oral Maxillofac Surg; 2000 Feb; 29(1):36-41. PubMed ID: 10691142
[TBL] [Abstract][Full Text] [Related]
10. Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy.
Rigaud J; Tiguert R; Decobert M; Hovington H; Latulippe E; Laverdiere J; Larue H; Lacombe L; Fradet Y
Prostate; 2004 Feb; 58(3):269-76. PubMed ID: 14743466
[TBL] [Abstract][Full Text] [Related]
11. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients.
Satoh T; Yang G; Egawa S; Addai J; Frolov A; Kuwao S; Timme TL; Baba S; Thompson TC
Cancer; 2003 Mar; 97(5):1225-33. PubMed ID: 12599229
[TBL] [Abstract][Full Text] [Related]
12. Accelerated tumor proliferation rates in locally recurrent prostate cancer after radical prostatectomy.
Connolly JA; Presti JC; Cher ML; Chew K; Shinohara K; Carroll PR
J Urol; 1997 Aug; 158(2):515-8. PubMed ID: 9224336
[TBL] [Abstract][Full Text] [Related]
13. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x.
Pollack A; Cowen D; Troncoso P; Zagars GK; von Eschenbach AC; Meistrich ML; McDonnell T
Cancer; 2003 Apr; 97(7):1630-8. PubMed ID: 12655519
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of the nuclear proliferative index (Ki-67) in benign prostate, prostatic intraepithelial neoplasia, and prostatic carcinoma.
Tamboli P; Amin MB; Schultz DS; Linden MD; Kubus J
Mod Pathol; 1996 Oct; 9(10):1015-9. PubMed ID: 8902840
[TBL] [Abstract][Full Text] [Related]
15. Mutated p53 protein expression and proliferative activity in advanced gastric cancer.
Ikeguchi M; Saito H; Kondo A; Tsujitani S; Maeta M; Kaibara N
Hepatogastroenterology; 1999; 46(28):2648-53. PubMed ID: 10522058
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy.
Quinn DI; Henshall SM; Head DR; Golovsky D; Wilson JD; Brenner PC; Turner JJ; Delprado W; Finlayson JF; Stricker PD; Grygiel JJ; Sutherland RL
Cancer Res; 2000 Mar; 60(6):1585-94. PubMed ID: 10749127
[TBL] [Abstract][Full Text] [Related]
17. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
18. Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression.
Cheng L; Pisansky TM; Sebo TJ; Leibovich BC; Ramnani DM; Weaver AL; Scherer BG; Blute ML; Zincke H; Bostwick DG
Clin Cancer Res; 1999 Oct; 5(10):2820-3. PubMed ID: 10537347
[TBL] [Abstract][Full Text] [Related]
19. Prediction of biochemical relapse for stage pT3 prostate cancer following radical prostatectomy.
Wu TT; Wang JS; Lu CM; Lee YH; Huang JK
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Feb; 63(2):124-30. PubMed ID: 10677923
[TBL] [Abstract][Full Text] [Related]
20. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression.
Baretton GB; Klenk U; Diebold J; Schmeller N; Löhrs U
Br J Cancer; 1999 May; 80(3-4):546-55. PubMed ID: 10408865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
